3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
16
Phase 2
4
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
2
Meningioma
2
Lymphoma, B-Cell
2
Glioma
2
Glioblastoma
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor, Adult
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, B-Cell
1
Carcinoma, Hepatocellular
1
Carcinoma in Situ
1
Carcinoma
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Docetaxel
43
enzalutamide
31
Prednisone
25
Abiraterone Acetate
24
Magnetic Resonance Spectroscopy
18
abiraterone
15
pembrolizumab
14
bicalutamide
14
Radiotherapy
14
Cyclophosphamide
13
darolutamide
12
Leuprolide
12
Goserelin
12
apalutamide
10
Ipilimumab
10
olaparib
9
Specimen Handling
9
Radiosurgery
9
Radiation
9
Injections
9
Biopsy
9
Pluvicto
8
Paclitaxel
8
Radiotherapy, Intensity-Modulated
7
Carboplatin
7
sargramostim
6
fludarabine
6
cabazitaxel
6
Sirolimus
6
Nivolumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Prostatic Neoplasms
×
Magnetic Resonance Imaging
×
Clear all
NCT02911467
2020-07-24
MR
University of California, San Francisco
Phase 1
Terminated
8 enrolled